| Politician | Action | Description | Traded |
|---|---|---|---|
| Buy | ImmunityBio, Inc. | Sep 30, 2026 | |
| Buy | ImmunityBio, Inc. | Sep 28, 2026 | |
| Sell | Daniel Goldman Grandchildren | Mar 6, 2023 | |
| Sell | ImmunityBio, Inc. | Mar 6, 2023 |
This page tracks congressional stock trading activity in ImmunityBio, Inc. (IBRX) in the Healthcare sector. Disclosed Capitol has indexed 4 disclosed congressional trades involving IBRX. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of October 2026 — Disclosed Capitol has tracked 4 disclosed congressional trades in ImmunityBio, Inc. (IBRX) — 2:1 buy-heavy ratio — led by Lisa McClain (R).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Sep 30, 2026 | Lisa McClain | R | Buy | $1,001 - $15,000 |
| Sep 28, 2026 | Lisa McClain | R | Buy | $1,001 - $15,000 |
| Mar 6, 2023 | Daniel Goldman | D | Unknown | $1,001 - $15,000 |
| Mar 6, 2023 | Daniel Goldman | D | Sell | $1,001 - $15,000 |
Across the 4 disclosed congressional trades in ImmunityBio, Inc. (IBRX), members of Congress have reported 2 buys and 1 sell. The average 30-day alpha vs. the S&P 500 is -1.16%.
For fiscal year 2025, ImmunityBio, Inc. reported revenue of $113.3M and net income of -$351.4M, per SEC filings.
Most recent reported quarter: Q2 FY2026 — revenue $51.2M, net income -$230.4M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.